<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569892</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-33991</org_study_id>
    <nct_id>NCT02569892</nct_id>
  </id_info>
  <brief_title>Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration</brief_title>
  <official_title>Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled study of non-damaging photothermal macular grid laser versus
      sham laser therapy in patients with dry age-related macular degeneration (AMD) and large
      high-risk drusen. The goal of the study is to determine if this treatment will reduce macular
      drusen volume and also whether this might improve visual acuity or reduce the risk of
      conversion to advanced age-related macular degeneration defined as development of choroidal
      neovascularization or geographic atrophy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in macular drusen volume</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Mean change in macular drusen volume as measured on high-resolution spectral domain ocular coherence tomography (SD-OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Mean change in best-corrected visual acuity as measured using early treatment diabetic retinopathy study (ETDRS) chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of geographic atrophy (GA) or choroidal neovascularization (CNV)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of subjects who develop geographic atrophy or choroidal neovascularization by 24 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Retinal Drusen</condition>
  <arm_group>
    <arm_group_label>Laser Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-threshold laser utilizing Pascal laser with endpoint-management software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Laser Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham laser treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>macular laser treatment</intervention_name>
    <description>Sub-threshold macular laser treatment with Pascal laser Endpoint Management System</description>
    <arm_group_label>Laser Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham macular laser treatment</intervention_name>
    <description>Sham macular laser treatment with Pascal laser power setting of zero</description>
    <arm_group_label>Sham Laser Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Older than 60 years of age.

          2. Male or female patients with nonexudative AMD with a drusen volume of of at least
             0.03mm3 in the central 3mm circle

          3. Adequate pupil dilatation and clear media to perform colour, red-free imaging and
             fundus fluorescein angiography, fundus autofluorescence imaging and OCT.

          4. Able to give an informed consent.

        Exclusion Criteria:

          1. Presence of signs of advanced AMD, such as CNV, haemorrhages or macular atrophy based
             on OCT and fundus autofluorescence photography (FAF).

          2. Previous macular laser treatment.

          3. Any previous ocular condition that may be associated with a risk of developing macular
             oedema.

          4. Vitreomacular traction determined clinically and /or by OCT, which in the opinion of
             the investigator, contributes to the macular oedema (associated or causing a
             detachment of the fovea).

          5. Presence of other macular disease such as epiretinal membrane, macular telangiectasia.

          6. Important known allergies to sodium fluorescein dye used in angiography.

          7. Ocular or periocular infections.

          8. Planned intra-ocular surgery within one year.

          9. Patient is unavailable for follow-up visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Sanislo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Steven R. Sanislo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Drusen</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

